Patents by Inventor Koichi Yamanishi
Koichi Yamanishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140093526Abstract: The present invention addresses the problem of providing a vaccine which as yet has not been provided for the disease HHV-6B, which is the cause of exanthema subitum in infants, and the problem of providing an effective screening method for other therapeutic drugs. The above-mentioned problems are solved by providing an epitope specific to HHV-6B, of the amino acid sequence (QALCEGGHVFYNP) represented by positions 484 to 496 of SEQ ID NO: 2 or a modified sequence thereof, wherein the epitope either has a sequence comprising at least five consecutive amino acids including at least E, or a sequence that preserves the 487th C and 489th G when E is changed to Q.Type: ApplicationFiled: April 15, 2011Publication date: April 3, 2014Applicants: The Research Foundation for Microbial Diseases of Osaka University, National Institute of Biomedical InnovationInventors: Yasuko Mori, Koichi Yamanishi, Michiaki Takahashi
-
Publication number: 20120220028Abstract: Disclosed is an enhancer for a viral promoter such as a promoter that can induce expression selectively and strongly in immunocompetent cells (e.g., lymphocytes) or blood cells. It is found unexpectedly that an intron has the above-mentioned enhancer activity. Thus, it is found that an enhancer for a promoter, which comprises an intron sequence for a major immediate early gene (MIE) of human herpes virus-6 (HHV-6) (particularly HHV-6B) or a fragment of the intron sequence, has a potent promoter activity.Type: ApplicationFiled: September 3, 2010Publication date: August 30, 2012Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITYInventors: Masaaki Matsuura, Masaya Takemoto, Tetsuo Koshizuka, Koichi Yamanishi, Yasuko Mori
-
Publication number: 20120129263Abstract: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided.Type: ApplicationFiled: August 19, 2011Publication date: May 24, 2012Inventors: Yasuko Mori, Kenjiro Tadagaki, Masaya Takemoto, Michiaki Takahashi, Koichi Yamanishi
-
Patent number: 8148060Abstract: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided.Type: GrantFiled: June 4, 2010Date of Patent: April 3, 2012Assignee: The Research Foudation for Microbial Diseases of Osaka UniversityInventors: Yasuko Mori, Kenjiro Tadagaki, Masaya Takemoto, Michiaki Takahashi, Koichi Yamanishi
-
Patent number: 8013140Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: GrantFiled: August 21, 2008Date of Patent: September 6, 2011Assignee: The Resarch Foundation for Microbial Diseases of Osaka UniverstiyInventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Patent number: 8013139Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: GrantFiled: August 21, 2008Date of Patent: September 6, 2011Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Patent number: 8008467Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: GrantFiled: September 5, 2006Date of Patent: August 30, 2011Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Publication number: 20110070651Abstract: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided.Type: ApplicationFiled: June 4, 2010Publication date: March 24, 2011Inventors: Yasuko Mori, Kenjiro Tadagaki, Masaya Takemoto, Michiaki Takahashi, Koichi Yamanishi
-
Patent number: 7820436Abstract: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided.Type: GrantFiled: May 8, 2009Date of Patent: October 26, 2010Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Yasuko Mori, Kenjiro Tadagaki, Masaya Takemoto, Michlaki Takahashi, Koichi Yamanishi
-
Publication number: 20100119550Abstract: The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene.Type: ApplicationFiled: November 24, 2005Publication date: May 13, 2010Inventors: Yasuyuki Gomi, Michiaki Takahashi, Koichi Yamanishi
-
Publication number: 20100005536Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: ApplicationFiled: September 5, 2006Publication date: January 7, 2010Applicant: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Publication number: 20090253208Abstract: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided.Type: ApplicationFiled: May 8, 2009Publication date: October 8, 2009Inventors: Yasuko Mori, Kenjiro Tadagaki, Masaya Takemoto, Michlaki Takahashi, Koichi Yamanishi
-
Publication number: 20090214579Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: ApplicationFiled: August 21, 2008Publication date: August 27, 2009Inventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Publication number: 20090208516Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: ApplicationFiled: August 21, 2008Publication date: August 20, 2009Inventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Publication number: 20080226677Abstract: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided.Type: ApplicationFiled: May 12, 2004Publication date: September 18, 2008Inventors: Yasuko Mori, Kenjiro Tadagaki, Masaya Takemoto, Michiaki Takahashi, Koichi Yamanishi
-
Patent number: 6653069Abstract: Disclosed is a method for quality control of an attenuated varicella live vaccine, which comprises subjecting the genomic DNA of a sample varicella vaccine virus to sequence analysis and confirming that the genomic DNA of the sample varicella vaccine virus conserves the 5,745th G, the 105,356th C, the 105,544th G, the 106,262nd C and the 107,252nd C without suffering mutation, wherein the nucleotide numbers are in accordance with the nucleotide numbering system of the nucleotide sequence of the genomic DNA of the varicella virus Dumas strain of SEQ ID NO: 1.Type: GrantFiled: August 15, 2001Date of Patent: November 25, 2003Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Yasuyuki Gomi, Hiroki Sunamachi, Michiaki Takahashi, Koichi Yamanishi
-
Publication number: 20030082210Abstract: Disclosed is a method for quality control of an attenuated varicella live vaccine, which comprises subjecting the genomic DNA of a sample varicella vaccine virus to sequence analysis and confirming that the genomic DNA of the sample varicella vaccine virus conserves the 5,745th G, the 105,356th C, the 105,544th G, the 106,262nd C and the 107,252nd C without suffering mutation, wherein the nucleotide numbers are in accordance with the nucleotide numbering system of the nucleotide sequence of the genomic DNA of the varicella virus Dumas strain of SEQ ID NO: 1.Type: ApplicationFiled: August 15, 2001Publication date: May 1, 2003Inventors: Yasuyuki Gomi, Hiroki Sunamachi, Michiaki Takahashi, Koichi Yamanishi
-
Patent number: 6242429Abstract: Antiviral Ara-A derivatives having resistance to metabolism by adenosinedeaminase (ADA) are 2-substituted arabinosyladenine derivatives represented by the formula (I) and pharmaceutically acceptable salts and hydrates thereof: wherein Z is alkyl having at least 4 carbon atoms, alkenyl or alkynyl and R is hydrogen or lower alkyl. The compounds are useful as therapeutic or preventive agents for diseases infected by DNA virus such as herpes simplex virus (HSV), herpes zoster virus, cytomegalovirus (CMV), adenovirus, hepatitis virus or vaccinia virus. As compared with Ara-A, they not only show good activity in blood with an excellent sustaining property but also are capable of being orally administered without substantial loss of pharmaceutical effectiveness due to metabolism by ADA.Type: GrantFiled: June 24, 1999Date of Patent: June 5, 2001Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Toshio Yamada, Koichi Yamanishi
-
Patent number: 5853981Abstract: The present invention relates to two primers for amplifying a cytomegalovirus (CMV) nucleic acid suitable for a nucleic acid sequence-based amplification (NASBA) using a DNA-dependent RNA polymerase, a first primer containing a promoter sequence and a nucleic acid sequence consisting of at least fifteen continuous bases selected from the nucleic acid sequence of SEQ ID NO:1; a second primer containing a nucleic acid sequence consisting of at least fifteen continuous bases selected from the nucleic acid sequence of SEQ ID NO:2, NO:3 or NO:4; a detecting probe and/or a capturing probe containing a nucleic acid sequence consisting of at least continuous fifteen bases selected from the nucleic acid sequence(s) of SEQ ID NO:5, NO:6 and/or NO:7 wherein said sequence is modified if necessary; a reagent kit for detecting a CMV containing the above-mentioned primers and probes; and a nucleic acid sequence-based amplification (NASBA) using said primers.Type: GrantFiled: April 18, 1997Date of Patent: December 29, 1998Assignee: Toyo Boseki Kabushiki KaishaInventors: Motohiro Kondo, Toshiya Aono, Masaya Segawa, Koichi Yamanishi, Kazuhiro Kondo, Keiko Taya